Eurocine Vaccines has received notice of allowance in the US for one of its patent applications. The patent application, involving the company´s nasal influenza vaccine candidate Immunose™ FLU, has been examined and is allowed for issuance as a patent.

“We are pleased that one of our applications has been allowed by the U.S. Patent Office and we are encouraged to continue our systematic work to protect our rights”, said CSO Dr. Anna-Karin Maltais.

“This notice of allowance, in the world´s biggest pharmaceutical market, strengthens us in our discussions with potential partners and in our further development of Immunose™ FLU“, said CEO Dr. Hans Arwidsson.

For more information, please contact:

Hans Arwidsson, Ph.D., MBA

CEO of Eurocine Vaccines AB hans.arwidsson@eurocine-vaccines.com +46 70 634 0171

This information is information that Eurocine Vaccines AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, on April 24th 2017.

Vill du följa Eurocine Vaccines utveckling lättare?

Ta del del av pressreleaser, nyheter och artiklar kring vaccinering och influensa.
Välj vilken information som intresserar dig genom att fylla i fälten nedan.